|
|
|
|
|
|
|
|
"All members of the Panel have a keen interest in innovative improvements in the area of ovarian cancer and see a great opportunity to advance the previous learning with Oregovomab in the context of combination therapies to better access the potential of the immune response to bring clinical benefit to ovarian cancer patients," commented Dr. Nicodemus. "We are excited about the potential of the approach for these three planned clinical trials."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.